Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Regnum
New York, New York, United States
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
Regnum holds U.S. commercial rights from CytoDyn to leronlimab (PRO 140), a CCR5-targeting monoclonal antibody for HIV, which met the primary endpoint in a Phase 3 trial in highly treatment‑experienced HIV patients; however, the biologics license application for multidrug‑resistant HIV was voluntarily withdrawn in 2022 after FDA refusal‑to‑file issues, and Regnum currently has no direct clinical development authority over the program.[3][5][6]
- Therapeutic areas
- Infectious Diseases
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
02
Partnerships
CytoDyn (license and commercialization agreements granting Regnum U.S. commercial rights to leronlimab in HIV indications)[3][5][9]
Beyond the preview
Go deeper on Regnum.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Regnum.